Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Jul 18;153(7):e180996.
doi: 10.1001/jamasurg.2018.0996. Epub 2018 Jul 18.

Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer

Georgios Antonios Margonis  1 , Stefan Buettner  1   2 , Nikolaos Andreatos  1 , Yuhree Kim  1 , Doris Wagner  3 , Kazunari Sasaki  4 , Andrea Beer  5 , Christoph Schwarz  5 , Inger Marie Løes  6   7 , Maria Smolle  8 , Carsten Kamphues  9 , Jin He  1 , Timothy M Pawlik  10   11 , Klaus Kaczirek  5 , George Poultsides  12 , Per Eystein Lønning  6   7 , John L Cameron  1 , Richard A Burkhart  1 , Armin Gerger  8 , Federico N Aucejo  4 , Martin E Kreis  9 , Christopher L Wolfgang  1 , Matthew J Weiss  1
Affiliations
Comparative Study

Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer

Georgios Antonios Margonis et al. JAMA Surg. .

Abstract

Importance: BRAF mutations are reportedly associated with aggressive tumor biology. However, in contrast with primary colorectal cancer, the association of V600E and non-V600E BRAF mutations with survival and recurrence after resection of colorectal liver metastases (CRLM) has not been well studied.

Objective: To investigate the prognostic association of BRAF mutations with survival and recurrence independently and compared with other prognostic determinants, such as KRAS mutations.

Design, setting, and participants: In this cohort study, all patients who underwent resection for CRLM with curative intent from January 1, 2000, through December 31, 2016, at the institutions participating in the International Genetic Consortium for Colorectal Liver Metastasis and had data on BRAF and KRAS mutational status were retrospectively identified. Multivariate Cox proportional hazards regression models were used to assess long-term outcomes.

Interventions: Hepatectomy in patients with CRLM.

Main outcomes and measures: The association of V600E and non-V600E BRAF mutations with disease-free survival (DFS) and overall survival (OS).

Results: Of 853 patients who met inclusion criteria (510 men [59.8%] and 343 women [40.2%]; mean [SD] age, 60.2 [12.4] years), 849 were included in the study analyses. Forty-three (5.1%) had a mutated (mut) BRAF/wild-type (wt) KRAS (V600E and non-V600E) genotype; 480 (56.5%), a wtBRAF/wtKRAS genotype; and 326 (38.4%), a wtBRAF/mutKRAS genotype. Compared with the wtBRAF/wtKRAS genotype group, patients with a mutBRAF/wtKRAS genotype more frequently were female (27 [62.8%] vs 169 [35.2%]) and 65 years or older (22 [51.2%] vs 176 [36.9%]), had right-sided primary tumors (27 [62.8%] vs 83 [17.4%]), and presented with a metachronous liver metastasis (28 [64.3%] vs 229 [46.8%]). On multivariable analysis, V600E but not non-V600E BRAF mutation was associated with worse OS (hazard ratio [HR], 2.76; 95% CI, 1.74-4.37; P < .001) and DFS (HR, 2.04; 95% CI, 1.30-3.20; P = .002). The V600E BRAF mutation had a stronger association with OS and DFS than the KRAS mutations (β for OS, 10.15 vs 2.94; β for DFS, 7.14 vs 2.27).

Conclusions and relevance: The presence of the V600E BRAF mutation was associated with worse prognosis and increased risk of recurrence. The V600E mutation was not only a stronger prognostic factor than KRAS but also was the strongest prognostic determinant in the overall cohort.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Study Flowchart
CRLM indicates colorectal liver metastases; mut, mutated genotype; and wt, wild-type genotype.
Figure 2.
Figure 2.. Kaplan-Meier Estimates of Overall Survival
For wtKRAS/wtBRAF vs mutKRAS/wtBRAF, P = .002; mutKRAS /wtBRAF vs V600E BRAF, P = .008. mut indicates mutated genotype; wt, wild-type genotype.
See this image and copyright information in PMC

Comment in

References

    1. Søreide K, Sandvik OM, Søreide JA. KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: a biomarker of cancer biology or a byproduct of patient selection? Cancer. 2014;120(24):-. - PMC - PubMed
    1. Margonis GA, Kim Y, Spolverato G, et al. . Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg. 2015;150(8):722-729. - PMC - PubMed
    1. Margonis GA, Kim Y, Sasaki K, Samaha M, Amini N, Pawlik TM. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer. 2016;122(17):2698-2707. - PubMed
    1. Vauthey JN, Zimmitti G, Kopetz SE, et al. . RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619-626. - PMC - PubMed
    1. Frankel TL, Vakiani E, Nathan H, et al. . Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Cancer. 2017;123(4):568-575. - PMC - PubMed

Publication types

MeSH terms